Revance Therapeutics (RVNC) Reports Q2 Loss of $0.90/Share
Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.90), versus ($0.88) reported last year.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.
Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($0.90), versus ($0.88) reported last year.
For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.